mlkrborn
12 년 전
NAME CHANGE TO MEIP and significant developments
Novogen Announces Merger Agreement With Kai Medical And Distribution Of Mei Pharma Shares
Press Release: Novogen – Fri, Jul 27, 2012 12:16 PM EDT
Email
Print
Companies:
MEI Pharma, Inc.
RELATED QUOTES
Symbol Price Change
MEIP 0.43 -0.03
SYDNEY, July 27, 2012 /PRNewswire/ -- Novogen today announced that it has entered into a merger agreement with Kai Medical, a United States based company, incorporated in Delaware, whose business is focused on sleep apnea therapy devices and wireless respiration monitoring technology. The agreement is subject to a number of conditions including completion of due diligence and shareholder approval.
"We are very pleased to be able to enter into a relationship with Kai Medical that provides Novogen shareholders with an opportunity to participate in the growth and success of Kai Medical's revolutionary sleep apnea therapy device," said William D. Rueckert, Chairman of the Board for Novogen. He continued, "The sleep apnea market, Worldwide is a rapidly growing market with tremendous opportunities for companies like Kai that have a product with a distinct performance advantages. There is a clear unmet need for patients with this condition for a convenient and effective therapy."
Bob Nakata, CEO of Kai Medical added, "Kai Medical has recently received its CE Mark for Kai Apnea, which is the key regulatory approval needed for sales in most of the world. Kai Apnea is more comfortable to use and will likely have higher compliance than most other sleep apnea devices. I believe that this will lead to strong growth in the coming years and am pleased that we can share this progress with Novogen shareholders through this transaction."
In addition to the merger agreement with Kai, Novogen today announced that in advance of the merger with Kai Medical and subject to shareholder approval, it will undertake a capital reduction and in specie distribution to the Novogen shareholders of the shares of MEI Pharma that it owns.
Mr. Rueckert stated, "It has been our intention for the past few years to put Novogen's largest and most important asset directly in the hands of our shareholders. This distribution will allow each of our shareholders to own their proportionate share of the MEI Pharma (Nasdaq: MEIP, formerly known as Marshall Edwards Inc) shares now held by Novogen, and also allow them to continue to hold their Novogen shares after the merger with Kai Medical."
The glucan technology assets which Novogen currently holds will not be acquired by Kai Medical in the merger and Novogen plans to complete the sale of those assets to TR Therapeutics, Inc., a privately held, US corporation, in the next few days.
Novogen expects to provide shareholders with full details of the merger proposal and in specie distribution within the next three weeks. The shareholders meeting is expected to be held in mid September.
Novogen Limited will be renamed to Kai Medical Holdings Limited when the merger becomes effective.
About Novogen Limited
Novogen Limited is an Australian biotechnology company based in Sydney, Australia. Novogen conducts research and development on oncology therapeutics through its subsidiary, MEI Pharma, Inc. More information on the Novogen group of companies can be found at www.novogen.com.
About Kai Medical, Inc.
Kai Medical develops and markets medical devices for sleep apnea therapy and devices to measure and monitor respiration wirelessly, with no contact, and from a distance. Kai Medical is based in Honolulu, Hawaii USA. More information on Kai Medical can be found at www.kaimedical.com.
richrichrich
13 년 전
Just read about the rights offering "deal"......Of any rights offering situation I've had happen in the past, usually with gold or oil mining/drilling type penny stocks, they've ended up in disaster shortly afterwards. In two different ones I can think of, they both ended up going chapter 11, just a few months after the rights offering was over. It seems like some sort of "desperation" effort, to try their best to keep the company from complete collapse. In both others I went through, they try this offering period to see if they can stimulate some buying interest, to keep it alive. Then meanwhile, if there's any sort of upward spike in the PPS, the "insiders" go ahead and dump their personally held shares. Why? Because they themselves know, it isn't going to work out. This way, they have cleared themselves of any sort of loss. Then they finally announce, "The rights offering didn't quite raise enough money to keep this thing alive, so unfortunately we'll have to cease operations". Then comes the bankruptcy, dissolution, chapter 11, etc.......I've never seen one of these things come out of it without some sort of shareholder "damage".......Might even be they need to "restructure", with a lovely reverse split afterwards........Oh well. I don't have much invested in it, so I'll ride it out, to see what happens(the usual stupidity)......LOL.
richrichrich
13 년 전
I thought that's why I'm seeing it on Fidelity fast quote, as a triangle with an exclamation point......Meaning, it has lost it's NASD status......Maybe it's just a warning, of impending doom......Today did it no honor......Sometimes these things recover nicely, to over a dollar per share, to retain their status.....I'd sure like to see some insider buying, indicating their "confidence"......
mlkrborn
13 년 전
Rights issuance:0.70 today
Marshall Edwards receives notice of effectiveness for rights offering to stockholders (MSHL) 0.72 : Under the terms of the rights offering, co will distribute one subscription right for each share of common stock owned to holders of record as of 5:00 p.m., Eastern time, on March 30, 2012. Each subscription right will entitle the holder to purchase one Unit, which consists of 0.5 shares of the co's common stock and a warrant to purchase 0.25 shares of the co's common stock. Holders of the co's outstanding Series A warrants will also receive one subscription right for each share of common stock issuable pursuant to such warrants.
Kurupt
13 년 전
9:03AM Marshall Edwards announced that it has set the record date and pricing terms for its previously announced rights offering to existing stockholders (MSHL) 0.68 : For every two Units purchased in the rights offering, stockholders will receive one share of common stock at a price of $0.89 per share, which represents a 10 percent discount to the volume-weighted average price of the Company's common stock for the 30 consecutive trading days ending on, and inclusive of, March 13, 2012, and warrants to purchase one-half of a share of common stock at an exercise price of $1.19 per share, which represents a 20 percent premium to the volume-weighted average price of the Company's common stock during the same period
http://finance.yahoo.com/marketupdate/inplay#mshl
Penny Roger$
13 년 전
$MSHL ~ Buy-ins ~ Naked Short List! In Charts and links! for Feb. 14th 2012 - Daily and Weekly views.
Chart results for you to ponder with me.. Certain charts may be reposted while on the Buy-ins website, Click next or previous at the top of the page to see my others.
~ Barchart: http://barchart.com/quotes/stocks/MSHL?
~ OTC Markets: http://www.otcmarkets.com/stock/MSHL/company-info
~ Google Finance: http://www.google.com/finance?q=MSHL
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=MSHL#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=MSHL+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=MSHL
Finviz: http://finviz.com/quote.ashx?t=MSHL
~ BusyStock: http://busystock.com/i.php?s=MSHL&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=MSHL&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=MSHL
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=MSHL
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=MSHL
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=MSHL
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=MSHL
~ MarketWatch: http://www.marketwatch.com/investing/stock/MSHL/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=MSHL
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=MSHL
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=MSHL&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=MSHL&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=MSHL&size=l&frequency=60&color=g
Volume, MACD, ADX 3 EMA Par sar - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=MSHL&time=8&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=2&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=16&lf=1&lf2=4&lf3=1024&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=25&y=5
RSI, Money Flow, Volume Accumulation, 3sma, Bollinger bands - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=MSHL&time=8&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=2&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=4&maval=9&uf=8&lf=2&lf2=512&lf3=4096&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=36&y=14
Price Channel, Momentum, Volatility Slow, P/E Ratio - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=MSHL&time=8&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=2&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=128&lf=65536&lf2=16384&lf3=16777216&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=28&y=15
Volume, MACD, ADX 3 EMA Par sar - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=MSHL&time=6&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=1&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=16&lf=1&lf2=4&lf3=1024&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=39&y=17
RSI, Money Flow, Volume Accumulation, 3sma, Bollinger bands - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=MSHL&time=6&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=1&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=4&maval=9&uf=8&lf=2&lf2=512&lf3=4096&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=35&y=12
Price Channel, Momentum, Volatility Slow, P/E Ratio - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=MSHL&time=6&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=1&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=128&lf=65536&lf2=16384&lf3=16777216&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=23&y=19
Twitter: @MACDgyver ---> MSHL <---
mlkrborn
13 년 전
MSHL $1.03; Marshall Edwards adds $2 mln in private placement (MSHL) 1.03 : Co has reached a definitive agreement with its majority shareholder, Novogen Limited (NVGN), to sell common stock in a private placement for gross proceeds of $2 million, before deducting fees and expenses of the offering, through the sale of ~1.94 million shares of common stock. The offering is expected to close by tomorrow, December 30, 2011, subject to certain customary closing conditions. The net proceeds from the offering will be used to continue development of Marshall Edwards' lead oncology drug candidates, including the submission of an Investigational New Drug (IND) application for ME-344 in the first quarter of 2012 and the completion of a Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumors in the second quarter of 2012.
GALGO
13 년 전
News out!!!!!!!!:
Link To This Article:
Marshall Edwards and Ausio Pharmaceuticals Announce Exclusive License Agreement
Date : 10/27/2011 @ 9:00AM
Source : PR Newswire
Stock : Marshall Edwards (MSHL)
Quote : 1.28 -0.03 (-2.29%) @ 8:00PM
Marshall Edwards and Ausio Pharmaceuticals Announce Exclusive License Agreement
print
Marshall Edwards (NASDAQ:MSHL)
Intraday Stock Chart
Today : Friday 28 October 2011
Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, and Ausio Pharmaceuticals, LLC, a biopharmaceutical company focused on the development of safe and effective medicines for the aging population, announced today the signing of an exclusive, royalty-bearing license agreement.
The agreement gives Ausio exclusive, worldwide rights under certain Marshall Edwards patents to develop, manufacture and sell products utilizing the isoflavone metabolite known as equol for non-oncology applications. In exchange, Marshall Edwards is entitled to receive royalty payments on sales of any potential Ausio products that contain equol. In addition, the agreement gives Marshall Edwards a royalty-free license to certain issued manufacturing-related intellectual property owned by Ausio. Further terms of the agreement were not disclosed.
"We are very pleased to enter into this licensing agreement with Ausio, our first since completing the acquisition of our isoflavone-based intellectual property portfolio earlier this year," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of Marshall Edwards. "This agreement demonstrates our commitment to maximizing the value of these assets while maintaining our focus on the clinical development of our two current lead oncology drug candidates, ME-143 and ME-344."
"This exclusive license to Marshall Edward's worldwide patents claiming the composition and therapeutic uses of equol further strengthens our global patent portfolio for S- and R-equol," said Richard L. Jackson, Ph.D., President and Chief Executive Officer of Ausio Pharmaceuticals. "S-equol, the S enantiomer of equol, is a first-in-class, non-hormonal, non-steroidal estrogen receptor beta agonist that is in Phase 2 clinical development for the treatment of vasomotor symptoms in postmenopausal women and benign prostatic hyperplasia in men, and for various topical uses."
About Ausio Pharmaceuticals
Ausio Pharmaceuticals, LLC, is a private biotechnology development company focused on the advancement of safe and effective medicines for the aging population. Ausio was founded in 2006 by Richard Jackson, Ph.D. based on technologies licensed from the Australian Health and Nutrition Association and Cincinnati Children's Hospital Medical Center. The Company has garnered a strong patent position for its lead compound, AUS 131 (also referred to as S-equol). It has rapidly developed AUS-131 by working with excellent service providers. Ausio's strategic goal is to collaborate with international pharmaceutical partners for AUS-131 in the U.S. and other markets worldwide. For further information on Ausio, please visit the Company's website at www.ausiopharma.com.
About Marshall Edwards
Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes lead candidate ME-143. The second is a mitochondrial inhibitor program that includes lead candidate ME-344. The Company initiated a Phase I clinical trial of intravenous ME-143 in September 2011 and expects to submit an IND application for ME-344 by the first quarter of 2012. For more information, please visit www.marshalledwardsinc.com.
Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.
SOURCE Marshall Edwards, Inc.; Ausio Pharmaceuticals
mlkrborn
13 년 전
MSHL $1.69 Marshall Edwards Announces $2 Million Private Placement
prnewswire
Related Quotes
Symbol Price Change
MSHL 1.69 +0.15
Press Release Source: Marshall Edwards, Inc. On Wednesday September 28, 2011, 9:00 am
SAN DIEGO, Sept. 28, 2011 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq:MSHL - News), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that it has entered into a definitive agreement with its majority shareholder, Novogen Limited, to sell common stock in a private placement for gross proceeds of $2 million, before deducting fees and expenses of the offering, through the sale of approximately 1.33 million shares of common stock. The offering is expected to close on September 30, 2011, subject to certain customary closing conditions.
"This transaction is another indication of Novogen's ongoing support of Marshall Edwards and our emerging oncology programs," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of Marshall Edwards. "Net proceeds from this offering will be used to continue development of our two lead drug candidates, ME-143 and ME-344, and will enable us to advance these programs to meaningful clinical data points next year that we believe can create significant value for our shareholders."
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Marshall Edwards, Inc. nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Marshall Edwards
Marshall Edwards, Inc. (Nasdaq:MSHL - News) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes lead candidate ME-143. The second is a mitochondrial inhibitor program that includes lead candidate ME-344. The Company initiated a Phase I clinical trial of intravenous ME-143 in September 2011 and expects to submit an IND application for ME-344 by the first quarter of 2012. For more information, please visit www.marshalledwardsinc.com.
mlkrborn
13 년 전
MSHL $2.11; Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
Related Quotes
Symbol Price Change
MSHL 2.11 -0.64
Press Release Source: Marshall Edwards, Inc. On Wednesday July 27, 2011, 9:00 am EDT
SAN DIEGO, July 27, 2011 /PRNewswire/ -- Marshall Edwards, Inc.(Nasdaq:MSHL - News), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced the publication of results from a pre-clinical study of NV-128 showing activity in chemotherapy-resistant ovarian cancer stem cells. NV-128 is the prodrug of the Company's investigational compound and lead mitochondrial inhibitor drug candidate, NV-344. The publication, entitled "Targeting the mitochondria activates two independent cell death pathways in the ovarian cancer stem cells," is available on the Molecular Cancer Therapeutics website and scheduled to print in the August issue of the journal. An abstract can be found at www.marshalledwardsinc.com/our-programs/scientific-publications.
"A major obstacle in the successful treatment of ovarian cancer is disease recurrence due in part to the outgrowth of chemotherapy-resistant ovarian cancer stem cells," said senior author Gil Mor, M.D., Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine. "This study shows that NV-128 can specifically target the mitochondriain patient-derived ovarian cancer stem cells to induce cell death in an otherwise chemo-resistant cell population. We believe these encouraging data provide sufficient proof of concept to warrant further study in ovarian cancer patients."
Previous studies conducted at Yale University showed that NV-128 is able to inhibit tumor growth in an ovarian cancer animal model without inducing significant toxicity, suggesting a sufficient therapeutic window that may allow compounds of this class to be safely administered to patients. Once administered, NV-128 is demethylated in vivo to NV-344, its active metabolite, which has been shown to be significantly more potent than NV-128 in pre-clinical research studies. Marshall Edwards plans to complete the required pre-clinical studies of NV-344 to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) by the first quarter of 2012.
"This study exemplifies the importance of our ongoing collaboration with Dr. Mor and his associates at Yale University as well as our continuing commitment to enhancing our pipeline of novel drug candidates," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of Marshall Edwards. "We are excited about the progress we are making with both of our lead candidates, NV-143 and NV-344, and look forward to reporting on their clinical development in the months ahead."
Hot Features
프리미엄
브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
MacFly
13 년 전
PoemStone
13 년 전
WARHAMMER
13 년 전
